A Review of Allogeneic Hematopoietic Stem Cell Transplantation in Metastatic Breast Cancer

Overview

Journal Int J Hematol Oncol Stem Cell Res

Specialty Hematology

Date 2018 Sep 21

PMID 30233772

Citations 1

Authors

Nuri Karadurmus

Ugur Sahin

Bilgin Bahadir Basgoz

Fikret Arpaci

Taner Demirer

Affiliations

Soon will be listed here.

Abstract

Breast cancer (BC) has a high mortality rate and metastatic BC is almost incurable despite hormonal therapy and chemotherapy. The second and third lines of chemotherapies usually yield transient responses and the median survival is generally as low as 18-24 months. Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) have been extensively investigated in this setting. The presence of immune mediated anti-tumor effects referred to as graft-versus-tumor (GvT) effects after allogeneic HSCT among patients with solid tumors have been clearly defined. The advantages of allogeneic HSCT over autologous HSCT for metastatic BC are i) cancer-free graft and ii) immune-mediated GvT effects mediated by human leukocyte antigen compatible donor T-cells. In conclusion, a GvT effect does exist against metastatic BC and play a key role in tumor response. This review aims to describe the background, rationale, and clinical results of allogeneic HSCT as a potential alternative treatment in metastatic BC.

Citing Articles

Examining the potentials of stem cell therapy in reducing the burden of selected non-communicable diseases in Africa.

Atewologun F, Okesanya O, Okon I, Kayode H, Ukoaka B, Olaleke N Stem Cell Res Ther. 2024; 15(1):253.

PMID: 39135088 PMC: 11321202. DOI: 10.1186/s13287-024-03864-4.

References

Holmberg L, Demirer T, Rowley S, Buckner C, Goodman G, Maziarz R . High-dose busulfan, melphalan and thiotepa followed by autologous peripheral blood stem cell (PBSC) rescue in patients with advanced stage III/IV ovarian cancer. Bone Marrow Transplant. 1998; 22(7):651-9. DOI: 10.1038/sj.bmt.1701398. View

Copelan E . Hematopoietic stem-cell transplantation. N Engl J Med. 2006; 354(17):1813-26. DOI: 10.1056/NEJMra052638. View

Pedrazzoli P, Ferrante P, Kulekci A, Schiavo R, De Giorgi U, Carminati O . Autologous hematopoietic stem cell transplantation for breast cancer in Europe: critical evaluation of data from the European Group for Blood and Marrow Transplantation (EBMT) Registry 1990-1999. Bone Marrow Transplant. 2003; 32(5):489-94. DOI: 10.1038/sj.bmt.1704153. View

Taylor 4th S, Knuiman M, Sleeper L, Olson J, Tormey D, Gilchrist K . Six-year results of the Eastern Cooperative Oncology Group trial of observation versus CMFP versus CMFPT in postmenopausal patients with node-positive breast cancer. J Clin Oncol. 1989; 7(7):879-89. DOI: 10.1200/JCO.1989.7.7.879. View

McSweeney P, Niederwieser D, Shizuru J, Sandmaier B, Molina A, Maloney D . Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood. 2001; 97(11):3390-400. DOI: 10.1182/blood.v97.11.3390. View

Eibl B, Schwaighofer H, Nachbaur D, Marth C, Gachter A, Knapp R . Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood. 1996; 88(4):1501-8. View

Davis B, Gelber R, Goldhirsch A, Hartmann W, Locher G, REED R . Prognostic significance of tumor grade in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasis. Cancer. 1986; 58(12):2662-70. DOI: 10.1002/1097-0142(19861215)58:12<2662::aid-cncr2820581219>3.0.co;2-y. View

Fisher B, Redmond C, Wickerham D, Rockette H, Brown A, Allegra J . Relation of estrogen and/or progesterone receptor content of breast cancer to patient outcome following adjuvant chemotherapy. Breast Cancer Res Treat. 1983; 3(4):355-64. DOI: 10.1007/BF01807588. View

Morecki S, Yacovlev E, Gelfand Y, Uzi I, Slavin S . Cell therapy with preimmunized effector cells mismatched for minor histocompatible antigens in the treatment of a murine mammary carcinoma. J Immunother. 2001; 24(2):114-21. View

10.

Carella A, Beltrami G, Lerma E, Cavaliere M, Corsetti M . Combined use of autografting and non-myeloablative allografting for the treatment of hematologic malignancies and metastatic breast cancer. Cancer Treat Res. 2002; 110:101-12. DOI: 10.1007/978-1-4615-0919-6_5. View

11.

Brunvand M, Bensinger W, Soll E, Weaver C, Rowley S, Appelbaum F . High-dose fractionated total-body irradiation, etoposide and cyclophosphamide for treatment of malignant lymphoma: comparison of autologous bone marrow and peripheral blood stem cells. Bone Marrow Transplant. 1996; 18(1):131-41. View

12.

Fisher B, Anderson S, Wickerham D, DeCillis A, Dimitrov N, Mamounas E . Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol. 1997; 15(5):1858-69. DOI: 10.1200/JCO.1997.15.5.1858. View

13.

Childs R, Chernoff A, Contentin N, Bahceci E, Schrump D, Leitman S . Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med. 2000; 343(11):750-8. DOI: 10.1056/NEJM200009143431101. View

14.

Peccatori J, Barkholt L, Demirer T, Sormani M, Bruzzi P, Ciceri F . Prognostic factors for survival in patients with advanced renal cell carcinoma undergoing nonmyeloablative allogeneic stem cell transplantation. Cancer. 2005; 104(10):2099-103. DOI: 10.1002/cncr.21477. View

15.

Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, CIVIDALLI G . Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998; 91(3):756-63. View

16.

Morecki S, Yacovlev E, Diab A, Slavin S . Allogeneic cell therapy for a murine mammary carcinoma. Cancer Res. 1998; 58(17):3891-5. View

17.

Hryniuk W, Bush H . The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol. 1984; 2(11):1281-8. DOI: 10.1200/JCO.1984.2.11.1281. View

18.

De Giorgi U, Demirer T, Wandt H, Taverna C, Siegert W, Bornhauser M . Second-line high-dose chemotherapy in patients with mediastinal and retroperitoneal primary non-seminomatous germ cell tumors: the EBMT experience. Ann Oncol. 2004; 16(1):146-51. DOI: 10.1093/annonc/mdi017. View

19.

Henderson I, Berry D, Demetri G, Cirrincione C, Goldstein L, Martino S . Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003; 21(6):976-83. DOI: 10.1200/JCO.2003.02.063. View

20.

Hortobagyi G . Treatment of breast cancer. N Engl J Med. 1998; 339(14):974-84. DOI: 10.1056/NEJM199810013391407. View